Fianu Labs steps into the limelight with $2m seed funding

Fianu

Fianu Labs, a company specialising in software governance automation, has announced its emergence from stealth mode.

The firm declared that it secured $2m in a seed funding round, generously backed by startup foundry DataTribe.

The company aims to resolve the disjunctions between various departments in software development such as engineering, quality assurance, security, risk, and audit. It accomplishes this by creating a continuous and immutable audit trail for every code modification. Fianu’s platform integrates seamlessly into the DevSecOps toolchain, generating an indelible ledger of attestations to ensure transparency and compliance.

With this fresh injection of capital, Fianu plans to broaden its initial focus beyond medical device and pharmaceutical companies. Though these regulated industries are their primary market, due to their need to meet stringent FDA requirements, the firm believes there’s an increasing need for governance solutions across all custom software environments.

Elaborating on the software’s capabilities, Fianu explained, “Fianu’s platform captures evidence across the DevSecOps toolchain mapped to internal policy during real-time, continuous audits against established risk controls and compliance frameworks. Each software release is accompanied by a Software Bill of Attestations (SBOA) designed to transmit immutable, audit-worthy evidence.”

The funding comes at a time when Fianu is experiencing high demand, especially in regulated industries that need to meet complex governance requirements. The company believes that this trend will extend to all firms that make custom software in the future.

This seed funding of $2m is the first publicly disclosed investment for Fianu Labs.

Keep up with all the latest FinTech news here.

Copyright © 2023 FinTech Global

Enjoying the stories?

Subscribe to our daily FinTech newsletter and get the latest industry news & research

Investors

The following investor(s) were tagged in this article.